These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 29466184)

  • 1. [Efficiency of primary prevention for diseases caused by atherosclerosis in patients at high cardiovascular risk in Russia and other European countries (Part 2)].
    Pogosova NV; Oganov RG; Boytsov SA; Ausheva AK; Sokolova OY; Kursakov AA; Pozdnyakov YM; Gomyranova NV; Karpova AV; Isakova SS; Salbieva AO; Yusubova AI; Gusarova TA; Lel'chuk IN; Allenov AM; Vinokurov VG; Strelkova SN; Klimova AO; Loshkarev YV; Rubanov RV
    Kardiologiia; 2017 Mar; 57(S3):5-16. PubMed ID: 29466184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy of primary prevention for atherosclerosis-induced diseases in patients with high cardiovascular risk in Russia and other European countries (Part 1)].
    Boytsov SA; Pogosova NV; Oganov RG; Ausheva AK; Sokolova OY; Kursakov AA; Pozdnyakov YM; Gomyranova NV; Karpova AV; Isakova SS; Salbieva AO; Yusubova AI; Lel'chuk IN; Allenov AM; Vinokurov VG; Strelkova SN; Klimova AO; Loshkarev YV; Rubanov RV
    Kardiologiia; 2017 SJan; 57(S1):333-344. PubMed ID: 29276906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions.
    Kotseva K; De Bacquer D; De Backer G; Rydén L; Jennings C; Gyberg V; Abreu A; Aguiar C; Conde AC; Davletov K; Dilic M; Dolzhenko M; Gaita D; Georgiev B; Gotcheva N; Lalic N; Laucevicius A; Lovic D; Mancas S; Miličić D; Oganov R; Pajak A; Pogosova N; Reiner Ž; Vulic D; Wood D; On Behalf Of The Euroaspire Investigators
    Eur J Prev Cardiol; 2016 Dec; 23(18):2007-2018. PubMed ID: 27638542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study.
    Halcox JP; Banegas JR; Roy C; Dallongeville J; De Backer G; Guallar E; Perk J; Hajage D; Henriksson KM; Borghi C
    BMC Cardiovasc Disord; 2017 Jun; 17(1):160. PubMed ID: 28623902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries.
    Kotseva K; Wood D; De Backer G; De Bacquer D; Pyörälä K; Reiner Z; Keil U;
    Eur J Cardiovasc Prev Rehabil; 2010 Oct; 17(5):530-40. PubMed ID: 20577089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Time for a European perspective on cardiovascular prevention].
    Nilsson PM; Perk J; Rydén L
    Lakartidningen; 2008 Apr 2-8; 105(14):1000-4. PubMed ID: 18478749
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacological treatment of hypertension and hyperlipidemia in Izhevsk, Russia.
    Cybulsky M; Cook S; Kontsevaya AV; Vasiljev M; Leon DA
    BMC Cardiovasc Disord; 2016 Jun; 16():122. PubMed ID: 27255373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A search for novel pathways of effective prevention of cardiovascular complications in patients with type 2 diabetes mellitus: advance trial].
    Karpov IuA; Shubina AT
    Kardiologiia; 2007; 47(10):90-5. PubMed ID: 18260953
    [No Abstract]   [Full Text] [Related]  

  • 9. Antihypertensive, antidiabetic and lipid-lowering treatment frequencies in France in 2010.
    Tuppin P; Ricci-Renaud P; de Peretti C; Fagot-Campagna A; Gastaldi-Menager C; Danchin N; Alla F; Allemand H
    Arch Cardiovasc Dis; 2013 May; 106(5):274-86. PubMed ID: 23769402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe.
    Thom S; Field J; Poulter N; Patel A; Prabhakaran D; Stanton A; Grobbee DE; Bots ML; Reddy KS; Cidambi R; Rodgers A
    Eur J Prev Cardiol; 2014 Feb; 21(2):252-61. PubMed ID: 23038750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global cardiometabolic risk profile in patients with hypertension: results from the Turkish arm of the pan-European GOOD survey.
    Kabakcı G; Aydın M; Demir I; Kırma C; Özerkan F
    Turk Kardiyol Dern Ars; 2010 Jul; 38(5):313-20. PubMed ID: 21200100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dietary management of patients at high risk for cardiovascular disease; EUROASPIRE V.
    Marques-Vidal P; Jankowski P; Reiner Ž; De Bacquer D; Kotseva K;
    Clin Nutr ESPEN; 2023 Jun; 55():144-150. PubMed ID: 37202038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arresting cardiovascular disease progression. Early treatment may counteract high risk.
    Ram CV; Vergne-Marini P
    Postgrad Med; 2004 Aug; 116(2):45-8. PubMed ID: 15323153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are pediatricians responsible for prevention of adult cardiovascular disease?
    McGill HC; McMahan CA; Gidding SS
    Nat Clin Pract Cardiovasc Med; 2009 Jan; 6(1):10-1. PubMed ID: 18957957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacologic interventions in primary prevention: lipid lowering drugs, aspirin, antiobesity drugs, and antihypertensive agents].
    Auer J; Berent R; Weber T; Porodko M; Mayr H; Maurer E; Eber B
    Wien Med Wochenschr; 2001; 151(1-2):13-7. PubMed ID: 11234591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ASPIRE-2-PREVENT: a survey of lifestyle, risk factor management and cardioprotective medication in patients with coronary heart disease and people at high risk of developing cardiovascular disease in the UK.
    Kotseva K; Jennings CS; Turner EL; Mead A; Connolly S; Jones J; Bowker TJ; Wood DA;
    Heart; 2012 Jun; 98(11):865-71. PubMed ID: 22581735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compliance with cardiovascular drug prevention measures in a general population: the Multidisciplinary Intervention in Primary Care (IMAP) study.
    Lopez-Carmona D; Bernal-Lopez M; Mancera-Romero J; Jansen-Chaparro S; Portales-Fernandez I; Baca-Osorio AJ; Perez-Gonzalez R; Tinahones FJ; Gomez-Huelgas R
    Eur J Prev Cardiol; 2012 Oct; 19(5):1074-81. PubMed ID: 21810843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of recent trial results on cardiovascular risk management (Hatter Institute Cardiac Horizons series).
    Cardiovasc J Afr; 2008; 19(6):328-31. PubMed ID: 19104733
    [No Abstract]   [Full Text] [Related]  

  • 19. Lipid-lowering pharmacotherapy in Central and Eastern European countries in cardiovascular prevention: self-reported prescription patterns of primary care physicians.
    Tomasik T; Windak A; Seifert B; Kersnik J; Kijowska V; Dubas K
    J Cardiovasc Pharmacol Ther; 2013 May; 18(3):234-42. PubMed ID: 23277158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges in preventing cardiovascular complications in type 2 diabetes in primary care.
    Ubink-Veltmaat LJ; Bilo HJ; Groenier KH; Rischen RO; Meyboom-de Jong B
    Eur J Gen Pract; 2005 Mar; 11(1):11-6. PubMed ID: 15841058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.